LumiraDx Ltd (NASDAQ:LMDX) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET

Company Participants

Colleen McMillen – Vice President-Communications

Ron Zwanziger – Chairman and Chief Executive Officer

Dorian LeBlanc – Chief Financial Officer

Pooja Pathak – Chief Product Officer

Conference Call Participants

Vijay Kumar – Evercore ISI

Jeffrey Cohen – Ladenburg Thalmann

Andrew Cooper – Raymond James

Operator

Hello, and welcome to LumiraDx First Quarter 2022 Earnings Call. All participants will be in the listen-only mode. [Operator Instructions]

I would now like to turn the conference over to Colleen McMillen, Vice President of Communications. Please go ahead, ma’am.

Colleen McMillen

Hello, everyone. We’d like to welcome you to today’s call to discuss LumiraDx’s first quarter 2022 financial results issued earlier today. With us are LumiraDx’s Chairman and CEO; Ron Zwanziger; Chief Financial Officer, Dorian LeBlanc; and Chief Product Officer, Pooja Pathak. The press release announcing our financial results is posted on the Investor Relations section of the company’s website at LumiraDx.com.

Before we begin, I would like to caution listeners that statements we make today other than historical facts, are forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Please be aware that all such forward-looking statements involve risks and uncertainties and such as those detailed in our annual report on Form 20-F for the year ended December 31, 2021, which was filed with the SEC on April 13, 2022, and other filings that we make with the SEC. Any forward-looking statements that we make must be considered in light of these factors. Actual results may vary materially.

Also, during the course of today’s call, we may refer to certain non-IFRS financial measures. Non-IFRS financial measures should not be considered in isolation from or as a substitute for financial information presented in compliance with IFRS. There is a reconciliation schedule showing the IFRS versus non-IFRS results currently available in our press release issued earlier today, which can be found on our website.

I will now turn the call over to Ron Zwanziger for opening remarks. We will then provide financial and business updates before answering questions. Ron?

Ron Zwanziger

Thanks, Colleen, and thank you all for joining our call today. Our company had a strong start to the year. We’ve continued to innovate on our platform to deliver the fastest test results on the market with lab comparable performance. As anticipated, we ended the quarter with approximately 25,000 instruments shipped across 100 countries. Customer receptivity continues to drive market adoption and use cases for our platform in health systems and community-based settings. We’ve also gained momentum with our R&D pipeline and product launches of assays for common health conditions. We believe that this progress will enable us to drive strong growth of non-COVID revenues in the medium term and deliver on our vision of transforming the $15 billion addressable market for point of care diagnostics.